Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia

(2011) Jun J Yang et al.   NATURE GENETICS

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia

(2010) J. D. Kawedia et al.   BLOOD

Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity

(2010) S-H Chen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881

(2010) Nicolas Sirvent et al.   EUROPEAN JOURNAL OF CANCER

Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia

(2009) J C Panetta et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004)

(2009) Anjo J Veerman et al.   LANCET ONCOLOGY

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

(2009) Ching-Hon Pui et al.   NEW ENGLAND JOURNAL OF MEDICINE

Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia

(2008) Lei Yang et al.   JOURNAL OF CLINICAL ONCOLOGY